How CDK4/6 Inhibitors Work: Holding the Cell-Cycle Brake

The Brake They Reinforce

In early G1, the retinoblastoma protein (RB) binds E2F transcription factors and keeps genes needed for DNA synthesis switched off. Growth signals raise cyclin D, which activates CDK4 and CDK6; these kinases phosphorylate RB, releasing E2F and committing the cell to divide.

CDK4/6 inhibitors block that phosphorylation, so RB stays active, E2F stays bound, and cells arrest in G1.

Why RB Must Be Intact

If a tumour has lost RB1, there is no brake to hold, and CDK4/6 inhibition does little. RB loss is uncommon in hormone-receptor-positive breast cancer, which is one reason the class works well there, but it is a recognised resistance mechanism.

Related pathway changes — CDKN2A loss, cyclin E (CCNE1) amplification, or activating CDK6 changes — can also blunt the effect because they let the cell cycle proceed around CDK4/6.

Combining With Endocrine Therapy

In hormone-receptor-positive breast cancer, oestrogen signalling drives cyclin D. Blocking that signal with an aromatase inhibitor or fulvestrant, and blocking CDK4/6 directly, hits the same axis at two points. The combination improves progression-free survival, and in some trials overall survival, versus endocrine therapy alone.

Abemaciclib is also used after surgery in higher-risk hormone-receptor-positive disease.

How the Three Drugs Differ

Palbociclib and ribociclib are given on a 3-weeks-on, 1-week-off schedule and cause dose-limiting neutropenia; ribociclib additionally requires QT-interval and liver monitoring. Abemaciclib is more potent against CDK4 than CDK6, is given continuously, causes more diarrhoea and less severe neutropenia, and has single-agent activity.

These differences affect monitoring and tolerability more than whether the mechanism engages.

Is There a Companion Diagnostic?

There is no molecular companion test for CDK4/6 inhibitors. Eligibility rests on the tumour being hormone-receptor-positive and HER2-negative by standard immunohistochemistry, not on sequencing CDK4, CDK6, CCND1 or RB1. Routine RB1 testing is not recommended, because RB loss is uncommon in this setting and a negative result would not currently change first-line treatment.

This contrasts with alpelisib, which does require a PIK3CA mutation. When a CDK4/6 inhibitor stops working, next-line choices are increasingly guided by sequencing for an ESR1, PIK3CA, AKT1, PTEN or BRCA alteration rather than by re-testing the CDK4/6 axis itself.

Key Takeaways

• ·CDK4/6 inhibitors stop RB phosphorylation, keeping the RB-E2F brake on and arresting cells in G1.
• ·They need an intact RB pathway; RB1 loss and cyclin E amplification cause resistance.
• ·Palbociclib, ribociclib and abemaciclib differ in schedule, toxicity and CDK4-versus-CDK6 selectivity.